CLINICAL_TRIALS
trial_result
· 2017-04-11
Clinical Trial Update: Erlotinib Therapy and Subsequent Development of Mechanisms of Secondary Resistance in Patients With NSCLC [Phase 2]
Summary
Phase 2 trial update examining erlotinib therapy and subsequent mechanisms of resistance in patients with non-small cell lung cancer.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: David M. Jackman, MD | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2017-04-11